The steep decline came after the company announced top-line results from a phase 2b clinical study evaluating SER-287 in treating ulcerative colitis (UC). There were three patient cohorts in the clinical study. Seres CEO Eric Shaff acknowledged that "these outcomes were not what we, nor the UC community, were hoping for."
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting